Titan Pharmaceuticals Stock (NASDAQ:TTNP)
Previous Close
$3.27
52W Range
$3.15 - $14.80
50D Avg
$4.00
200D Avg
$5.75
Market Cap
$3.09M
Avg Vol (3M)
$18.20K
Beta
1.13
Div Yield
-
TTNP Company Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
TTNP Performance
Peer Comparison
Ticker | Company |
---|---|
SNTI | Senti Biosciences, Inc. |
KTTA | Pasithea Therapeutics Corp. |
GOVX | GeoVax Labs, Inc. |
VCNX | Vaccinex, Inc. |
FHTX | Foghorn Therapeutics Inc. |
SABS | SAB Biotherapeutics, Inc. |
CVKD | Cadrenal Therapeutics, Inc. Common Stock |
LIXT | Lixte Biotechnology Holdings, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
INDP | Indaptus Therapeutics, Inc. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
PCSA | Processa Pharmaceuticals, Inc. |
THRD | Third Harmonic Bio, Inc. |
SLRX | Salarius Pharmaceuticals, Inc. |